BV
Bioventus Inc.
BVS · NASDAQ
$12.98 -2.26% (-$0.30)
1M -8.98%
Market Cap $884.8M
P/E Ratio 16.25x
Div. Yield -
ROE 28.39%
Bulios Fair Price
$9.43
27.3% downside
Current Price
$12.98
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BVS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
77 /100
Cheap P/S 1.52x
P/E 16.25x
P/B 3.88x
Growth
30 /100
Declining Book val. growth 17.28%
Rev. growth 3.52%
FCF growth N/A
Profitability
74 /100
Strong Op. margin 10.63%
Gross margin 68.00%
FCF margin 16.20%
Quality
89 /100
Excellent ROA 8.09%
ROIC 18.09%
Asset turnover 0.86x
Debt
51 /100
Moderate Int. coverage 2.94x
Debt/Equity 1.16x
Net debt/EBITDA 2.52x
Stability
58 /100
Moderate EPS volatility 79.84%
Beta 0.65x
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BVS
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Claypoole
Employees
950
Headquarters
Durham
Upcoming events
03 NOV
Earnings
Upcoming earnings report